Thymus Cancer

P2, N=38, Not yet recruiting, Sun Yat-sen University

We previously found an increase of serum biomarkers of inflammation in 25 of 44 (56,8%) TET patients after the second dose (T2) of mRNA vaccine (BNT162b2 from Pfizer-BioNTech), although none developed immune-related complications at this time point...These findings suggested that the COVID-19 vaccine-related inflammation induces the HDL remodeling with a reduction of anti-inflammatory small HDL class. Further studies need to clarify why the vaccine causes inflammation in about 50% of TET patients and whether such response is peculiar to COVID-19 vaccine or if it would be induced also by other mRNA vaccines.

Our findings reveal a disease-defining autoantibody repertoire in paraneoplastic pemphigus that corresponds with clinical manifestations and holds high potential for early cancer detection in patients with blistering disease.

Thus, the tailored therapeutic approach that is described here for lung cancer may extend to patients with mesothelioma, rather than the previous "one therapy fits all" approach. Progress in the rare thymic epithelial tumors has been less marked; however, recent insights into the biology of thymic tumors have resulted in the development of clinically relevant interventions.

In addition, four out of five clones exhibited upregulated transcription of IL-2 in the salivary glands of T/B cell-deficient RAG2-/- mice, suggesting that autoreactive T cells were enriched in the DP T cell population of SATB1cKO mice. These results suggest that unusual DP T cells in SATB1cKO mice may be involved in autoimmune pathogenesis in SATB1cKO mice.

P=N/A, N=70, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

CYFRA 21-1 emerges as a reliable diagnostic biomarker for distinguishing TC from other thymic masses. Moreover, it holds promise for prognosis evaluation and potentially for recurrence surveillance.

Knowledge of the immune cell composition and the tumor immune microenvironment of TETs is essential to understand the risks of paraneoplastic autoimmunity and treatment-related toxicity in the era of immunotherapy. This review synthesizes recent advances in thymic biology and tumor immunology to frame the immune landscape of TETs.

P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Using genetic methodologies, we identified a robust link between immune cells and both benign and malignant thymic tumors. This study highlights the distinct immune phenotypes between benign and malignant thymic tumors, shedding light on their immunological mechanisms and suggesting new avenues for clinical immunotherapy.

P1, N=126, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 126